US Tech 100

19,804.00

0.64%

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

OPGN

OpGen (OPGN)

OpGen Inc

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:OPGN

<< Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 Next >>

Date	Time	Source	Headline	Symbol	Company
01/18/2023	4:37PM	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:OPGN	OpGen Inc
01/18/2023	7:30AM	GlobeNewswire Inc.	OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update	NASDAQ:OPGN	OpGen Inc
01/17/2023	7:30AM	GlobeNewswire Inc.	OpGen Subsidiary Curetis Meets Several Key Milestones in FIND Collaboration Project	NASDAQ:OPGN	OpGen Inc
01/11/2023	4:38PM	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:OPGN	OpGen Inc
01/11/2023	4:30PM	GlobeNewswire Inc.	OpGen Announces Closing of $7.5 Million Public Offering	NASDAQ:OPGN	OpGen Inc
01/11/2023	7:03AM	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)	NASDAQ:OPGN	OpGen Inc
01/09/2023	6:02AM	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:OPGN	OpGen Inc
01/06/2023	8:00PM	GlobeNewswire Inc.	OpGen Announces Pricing of $7.5 Million Public Offering	NASDAQ:OPGN	OpGen Inc
01/05/2023	7:10AM	Edgar (US Regulatory)	Securities Registration Statement (s-1/a)	NASDAQ:OPGN	OpGen Inc
01/04/2023	4:49PM	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:OPGN	OpGen Inc
01/04/2023	4:30PM	GlobeNewswire Inc.	OpGen Announced 1-for-20 Reverse Stock Split	NASDAQ:OPGN	OpGen Inc
12/13/2022	4:28PM	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:OPGN	OpGen Inc
12/13/2022	9:05AM	AllPennyStocks.com	Micro Cap Bid Up On Clinical Trial Data	NASDAQ:OPGN	OpGen Inc
12/13/2022	7:30AM	GlobeNewswire Inc.	OpGen Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel	NASDAQ:OPGN	OpGen Inc
12/02/2022	11:14AM	Edgar (US Regulatory)	Securities Registration Statement (s-1)	NASDAQ:OPGN	OpGen Inc
11/10/2022	4:27PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:OPGN	OpGen Inc
11/10/2022	4:26PM	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:OPGN	OpGen Inc
11/10/2022	4:23PM	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:OPGN	OpGen Inc
11/10/2022	4:10PM	GlobeNewswire Inc.	OpGen Reports Third Quarter 2022 Financial Results and Provides Business Update	NASDAQ:OPGN	OpGen Inc
10/27/2022	7:30AM	GlobeNewswire Inc.	OpGen Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2022 and Provides Business Update	NASDAQ:OPGN	OpGen Inc
10/27/2022	7:30AM	GlobeNewswire Inc.	OpGen to Provide Business Update and Financial Results for the Third Quarter 2022 on November 10th at 4:30 p.m. Eastern Standard Time	NASDAQ:OPGN	OpGen Inc
10/25/2022	7:30AM	GlobeNewswire Inc.	OpGen Subsidiary Curetis and BioVersys Sign Collaboration Agreement for Clinical Trial Support	NASDAQ:OPGN	OpGen Inc
10/17/2022	4:20PM	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:OPGN	OpGen Inc
10/06/2022	4:43PM	Edgar (US Regulatory)	Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)	NASDAQ:OPGN	OpGen Inc
10/03/2022	4:20PM	GlobeNewswire Inc.	OpGen Announces Closing of $3.38 Million Registered Direct Offering	NASDAQ:OPGN	OpGen Inc
10/03/2022	11:20AM	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)	NASDAQ:OPGN	OpGen Inc
10/03/2022	7:30AM	GlobeNewswire Inc.	OpGen Announces Successful Completion of Clinical Trial Enrollment for Unyvero Urinary Tract Infection Panel	NASDAQ:OPGN	OpGen Inc
09/30/2022	4:17PM	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)	NASDAQ:OPGN	OpGen Inc
09/30/2022	4:13PM	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)	NASDAQ:OPGN	OpGen Inc
09/30/2022	11:22AM	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)	NASDAQ:OPGN	OpGen Inc